The global hyperparathyroidism treatment market size is expected to be worth USD 835.5 Million in 2025. It can reach a valuation of USD 1,350.4 Million by 2032. The market is anticipated to peak at a CAGR of 7.1% during the forecast period (2025-2032).
The surge in hyperparathyroidism (HPT) among postmenopausal women and the demand for therapies for the treatment of secondary HPT can drive the market growth. Additionally, advances in diagnostic tools and success in minimally invasive surgeries can augur favorably for the market.
However, the high costs of treatment and the side effects of calcimimetics can be a hurdle to the market growth.
Key Market Insights
The hyperparathyroidism treatment market is predicted to scale owing to the rise of endocrine diseases, the use of targeted therapies, and the development of orphan drugs.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/hyperparathyroidism-treatment-market
Hyperparathyroidism Treatment Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 835.5 Million |
|
Estimated Value by 2032 |
USD 1,350.4 Million |
|
Growth Rate |
7.1% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The hyperparathyroidism treatment market is expected to be driven by the rise of rare endocrine disorders and the complications arising in the form of SHPT. The combination of calcimimetics and vitamin D analogues for the treatment of HPT in pediatric patients led to the launch of such products. This is witnessed by the approval of ORKEDIA tablets by Kyowa Kirin Group in Japan on August 30, 2023, and their distribution among patients with SHPT.
The use of long-acting PTH analogs and nanoparticle delivery systems for being precise with treatments can drive the market demand significantly. Assessment of novel drugs in clinical studies and development of advanced imaging methods can provide early prevention strategies in the market.
Market Opportunities: Popularity of miRNA Gene Therapies to Boost Market Growth
Targeted therapies at miRNA genes can change the expression of parathyroid glands and raise the potential of their development. The successful changes witnessed in gene expression in mice models can be used in the regulation of cell growth, metabolism, and differentiation. The need for the study on the pathogenesis of HPT and technical developments in miRNA gene therapy can open new opportunities for manufacturers in the hyperparathyroidism treatment market.
Market Challenge: Limited Drug Development Pipeline for HPT
The limited drug development for HPT, owing to the rise of a few drug candidates for approval, can continue to be a hurdle for the market. The shift towards SHPT and the lack of development of treatments for primary hyperparathyroidism can limit the market growth. This can be seen by the lack of any news of HPT treatments from 2024.
Analyst’s View
Recent Developments
OPKO Health, Inc. released the results of the effects of RAYALDEE, an extended-release calcifediol (ERC), on November 02, 2023. The data displayed the effective treatment of SHPT and the slowdown of the progression of CKD.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :